The hypothalamic pituitary adrenal (HPA) axis is our central stress response system. FRAXA Research Foundation awarded Dr. Carolyn B. Smith $62,000 in funding in 2005 to explore the HPA axis in Fragile X mice. The results of their study indicate that, in FVB/NJ mice, the hormonal response to and recovery from acute stress is unaltered by the lack of Fragile X mental retardation protein. Results published.
Read moreTreatment Targets
Therapeutic Interventions in FMR1 Knockout and Transgenic Mice: Role of the FMR1 Gene
With a $229,000 grant from FRAXA Research Foundation in 2006, Drs. Richard Paylor, David Albeck, and Francis Brennan at the Baylor College of Medicine found that, in mice as in humans, the level of Fragile X protein in brain cells plays a prominent role in determining levels of activity and anxiety.
Read moreExamining the Amygdala in Mouse Models of Fragile X
With a $63,000 grant from FRAXA Research Foundation in 2006, Dr. Joseph LeDoux and his team at New York University studied the role of the amygdala in Fragile X syndrome using mouse models.
Read moreSocial Deficits in Fragile X Syndrome: Do Gene-Gene Interactions Play a Role?
With a $100,000 grant from FRAXA Research Foundation from 2005-2006, Drs. Jean Lauder and Sheryl Moy at the University of North Carolina looked for gene-gene interactions in Fragile X syndrome.
Read morePharmacologic Interventions in the Fmr1 KO Mouse
With $48,600 in grants from FRAXA Research Foundation over 2004-2006, Dr. Catherine Choi at Drexel University studied Fragile X knockout mice to determine future treatment targets for Fragile X syndrome in humans.
Read moreComposition and Dynamics of FMRP-Containing RNP Complexes
FRAXA Research Foundation funded a grant of $30,000 in 2005 to Dr. Barbara Bardoni at INSERM in France. The team works on the biochemistry of the Fragile X protein.
Read moreGenerating Human Neurons Carrying the Fragile X Mutation
With a $50,000 grant from FRAXA Research Foundation, Dr. Clive Svendsen and his team at the University of Wisconsin grew neural stem cells that expressed the Fragile X mutation to help scientists better understand the gene characteristics.
Read moreIsolating and Characterizing the mRNAs That Bind FMRP
With $60,000 in grants from FRAXA Research Foundation from 1998-1999, Dr. Robert Denman and his team at the New York State Institute for Basic Research explored how FMRP possibly functions.
Read moreTreatment of a Mouse Model of Fragile X Syndrome with MPEP
With a $49,000 grant from FRAXA Research Foundation in 2003, Dr. Linda Crnic at the University of Colorado continued studies of MPEP in Fragile X mice, exploring whether chronic use improves symptoms of Fragile X syndrome without impairing cognitive function.
Read moreIdentification of Specific RNA Targets of FMRP
With a $70,000 grant from FRAXA Research Foundation from 1999-2001, Dr. Robert Darnell and his team at Rockefeller University made significant contributions towards understanding how FMRP functions and how the brain is affected without it. Results published.
Read moreNeural Network Model of Working Memory in Fragile X Syndrome
With a $67,000 grant from FRAXA Research Foundation in 2000, Dr. Mina Johnson-Glenberg at the University of Wisconsin researched how long-term and working memory was affected in individuals with Fragile X syndrome.
Read moreMelatonin Clinical Trial in Fragile X
With a $60,000 grant from FRAXA Research Foundation from 1998-1999, Dr. Randi Hagerman and her team at the University of California studied the effects of different compounds on individuals with Fragile X syndrome, focusing specifically on melatonin. Results published.
Read moreReactivation of the FMR1 Gene in Fragile X Patients Cells in Culture
With a $62,000 grant from FRAXA Research Foundation from 1999-2000, Dr. Giovanni Neri and his team at Universita Cattolica del S. Cuore explored possible strategies to turn the Fragile X gene back on.
Read moreImproving Memory Reversal Testing and Treatment with AMPAkines in the Fragile X Knock-Out Mouse
A two year $62,000 FRAXA grant was been awarded to W. Ted Brown, MD, PhD from 1997-1998. The Principal Investigator at the Institute For Basic Research in New York aims to develop an improved test to show learning deficits in the FMR1 knock-out mouse model of Fragile X, and test experimental drugs (Ampakines) that may be effective in treating these deficits.
Read more